Tyrosine kinase inhibitorFDA-approvedFirst-line
Vemurafenib
How it works
Blocks the BRAF V600E mutation, a genetic abnormality that drives cancer cell growth, allowing the immune system to attack cancer cells.
Cancer types
Melanoma— BRAF V600E mutation
Efficacy
Studies show that around 50% of patients achieved an objective response, with a median overall survival of approximately 15.4 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Treatments for Hairy Cell Leukemia | Leukemia | phase-2 | — | Source → |
| Melanoma Cells May Develop Resistance to Cancer Drug | Melanoma | lab-study | — | Source → |
| Melanoma Cells Resist Vemurafenib through Mitochondrial Changes | Melanoma | lab-study | — | Source → |
| New Compound May Help Fight Melanoma Resistance | Melanoma | lab-study | — | Source → |
| Vemurafenib May Help Fight Melanoma by Triggering Cell Death | Melanoma | lab-study | — | Source → |
| Researchers Identify New Way to Overcome Resistance to Cancer Treatment | Melanoma | lab-study | — | Source → |
| Researchers Create Melanoma Cell Lines Resistant to Cancer Treatment | Melanoma | lab-study | — | Source → |
| Real-world study of melanoma treatment in Germany | Melanoma | observational | Median overall survival was 21.6 months in patients without brain metastases and 7.4 months in patients with brain metastases. | Source → |
| Cobimetinib Plus Vemurafenib Shows Antitumor Activity in Advanced Solid Tumors | Melanoma | phase-2 | The disease control rate was 68% and the objective response rate was 57%. | Source → |
| USP18 may help melanoma cells resist cancer treatment | Melanoma | lab-study | — | Source → |
| New Vemurafenib Derivatives Show Promise as Melanoma Treatment | Melanoma | lab-study | — | Source → |
| Switching to Atezolizumab After 3 Months May Not Help Advanced Melanoma Patients | Melanoma | phase-2 | Median progression-free survival was 13.9 months in patients who continued vemurafenib plus cobimetinib, compared to 5.9 months in those who switched to atezolizumab. | Source → |
| Researchers Identify Potential Target for Overcoming Melanoma Resistance | Melanoma | lab-study | — | Source → |
| Combination Therapy Shows Promise in Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | The disease control rate was 52% (95% CI, 35 to 65), and the objective response rate was 30% (95% CI, 14 to 50). | Source → |
| New way to deliver cancer drugs to melanoma cells | Melanoma | lab-study | Both DAB- and VEM-loaded NMs elicited enhanced response with respect to free drug treatments in 4 different melanoma cell lines. | Source → |
| Alternative mRNA Splicing in Melanoma Cells Resistant to Vemurafenib | Melanoma | lab-study | — | Source → |
| Vemurafenib's Side Effect Linked to Enzyme Inhibition | Melanoma | lab-study | — | Source → |
| BRAF Inhibitor Resistance Linked to Protein PYK2 in Melanoma | Melanoma | lab-study | Increased expressions of p-PYK2 in melanoma patients were positively correlated with advanced stage (p = 0.002), metastasis (p < 0.001), and Clark grade (p < 0.001), and were also associated with short overall survival [hazard ratio (HR) = 3.304, p = 0.007] and progression-free survival (HR = 2.930, p = 0.001). | Source → |
| Combining Palbociclib and Vemurafenib in Metastatic Melanoma Treatment | Melanoma | phase-1/2 | The median progression-free survival was 2.8 months, and 5 (27.8%) patients showed a clinical response. | Source → |
| Vemurafenib May Help Hairy Cell Leukemia Patients Before Standard Treatment | Leukemia | observational | After a standard course of cladribine chemotherapy, 18 patients (90%) experienced complete clinical remission and 2 patients (10%) experienced partial remission with residual splenomegaly. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.